Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339335 | 0.86 | S1PR1 (0.38) | S1PR1S1PR3S1PR5FFAR1 | |
| SCHEMBL2499500 | 0.86 | S1PR1 (0.36) | S1PR1S1PR3S1PR5FFAR1 | |
| SCHEMBL3338104 | 0.86 | S1PR1 (0.38) | S1PR1S1PR3S1PR5FFAR1 | |
| SCHEMBL2503216 | 0.85 | SMN1; SMN2 (0.43) | S1PR1S1PR3S1PR5FFAR1CNR1 | |
| SCHEMBL3339929 | 0.84 | S1PR1 (0.37) | S1PR1S1PR3S1PR5FFAR1CNR1 | |
| SCHEMBL3338446 | 0.84 | S1PR1 (0.40) | S1PR1S1PR3S1PR5FFAR1 | |
| SCHEMBL13303516 | 0.84 | S1PR1 (0.35) | S1PR1S1PR3S1PR5FFAR1CNR1 | |
| SCHEMBL3340292 | 0.84 | S1PR1 (0.35) | S1PR1S1PR3S1PR5FFAR1CNR2 | |
| SCHEMBL3338890 | 0.83 | S1PR1 (0.38) | S1PR1FFAR1 | |
| SCHEMBL3340921 | 0.83 | S1PR1 (0.38) | S1PR1S1PR3S1PR5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.